thyssenkrupp nucera AG & Co. KGaA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

thyssenkrupp nucera AG & Co. KGaA (ETR:NCH2) shareholders are probably feeling a little disappointed, since its shares fell 9.0% to €9.09 in the week after its latest third-quarter results. Things were not great overall, with a surprise (statutory) loss of €0.01 per share on revenues of €184m, even though the analysts had been expecting a profit. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

After the latest results, the consensus from thyssenkrupp nucera KGaA's ten analysts is for revenues of €806.5m in 2026, which would reflect a considerable 12% decline in revenue compared to the last year of performance. Statutory earnings per share are predicted to shoot up 63% to €0.21. Before this earnings report, the analysts had been forecasting revenues of €832.8m and earnings per share (EPS) of €0.21 in 2026. The consensus seems maybe a little more pessimistic, trimming their revenue forecasts after the latest results even though there was no change to its EPS estimates.

View our latest analysis for thyssenkrupp nucera KGaA

The average price target was steady at €11.80even though revenue estimates declined; likely suggesting the analysts place a higher value on earnings. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values thyssenkrupp nucera KGaA at €17.00 per share, while the most bearish prices it at €8.70. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that revenue is expected to reverse, with a forecast 9.8% annualised decline to the end of 2026. That is a notable change from historical growth of 26% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 3.8% annually for the foreseeable future. It's pretty clear that thyssenkrupp nucera KGaA's revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. Even so, earnings are more important to the intrinsic value of the business. The consensus price target held steady at €11.80, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on thyssenkrupp nucera KGaA. Long-term earnings power is much more important than next year's profits. We have forecasts for thyssenkrupp nucera KGaA going out to 2027, and you can see them free on our platform here.

We don't want to rain on the parade too much, but we did also find 1 warning sign for thyssenkrupp nucera KGaA that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.